We highly recommend enabling Javascript while using the BlackBoxRX site.



  • Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.
  • Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor ANC weekly on therapy.
  • Interrupt deferiprone therapy if neutropenia develops.
  • Interrupt deferiprone therapy if¬†infection develops, and monitor the ANC more frequently.
  • Advise patients taking deferiprone to report immediately any symptoms indicative of infection.

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts


Updated January 2018